2018 Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Assessment and Insights - ResearchAndMarkets.com

DUBLIN--()--The "Attention Deficit Hyperactivity Disorder (ADHD): Pipeline Assessment and Insights" report has been added to ResearchAndMarkets.com's offering.

Attention Deficit Hyperactivity Disorder (ADHD): Pipeline Assessment and Insights report delivers an in-depth understanding of the disease, highlights all the pipeline products in different phases of development for the disease including the Suspended products and outlines in detail the drug profiles of key Pipeline therapies in the disease area.

Key Topics Covered:

1 Tables & Figures

2 Attention Deficit Hyperactivity Disorder (ADHD) Disease

2.1 Disease Overview

2.1.1 Disease Definition

2.1.2 Disease Epidemiology

2.1.3 Current Treatment Options

2.1.4 Key unmet needs

3 Pipeline Assessment

3.1 Overview

3.2 Strategic Review of the Pipeline

3.3 Pipeline analysis by Phases of Development

3.3.1 NDA/BLA Filed

3.3.2 Phase III Pipeline

3.3.3 Phase II Pipeline

3.3.4 Phase I Pipeline

3.3.5 Preclinical Pipeline

3.3.6 Discovery Pipeline

3.4 Pipeline Analysis by Mechanism of Action

3.5 Pipeline Analysis by Novelty of Mechanism of Action

3.6 Suspended and Terminated products

3.7 Attention Deficit Hyperactivity Disorder (ADHD) - Promising Therapies in Pipeline

3.7.1 SPN-810

3.7.2 Dasotraline

3.7.3 SPN 812

3.7.4 KP415

Companies Mentioned

  • Mitsubishi Tanabe Pharma
  • Menarini
  • GlaxoSmithKline
  • Endo International
  • Aspen Pharmacare
  • Faes Farma
  • Dong-A Socio Holdings
  • Hanmi Pharmaceutical
  • Abdi Ibrahim
  • Novartis
  • Roche
  • Daiichi Sankyo
  • Merck & Co
  • Astellas Pharma
  • AstraZeneca
  • Esteve
  • Daewoong Pharmaceutical
  • Innoviva
  • Vectura
  • Schering-Plough
  • Teva Pharmaceutical Industries
  • UCB
  • Celltech Group
  • Cephalon
  • Ception Therapeutics
  • Kyowa Hakko Kirin
  • Lonza
  • GC Pharma
  • PARI Medical Holding
  • Boehringer Ingelheim
  • Pfizer
  • Theravance Biopharma
  • Regeneron Pharmaceuticals
  • Sanofi
  • Pearl Therapeutics

For more information about this report visit https://www.researchandmarkets.com/research/jdnhfs/2018_attention?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs